Anrukinzumab
Anrukinzumab
Anrukinzumab (pronounced as an-ru-kin-zu-mab) is a monoclonal antibody designed for the treatment of certain autoimmune diseases. It is an experimental drug that has been studied in clinical trials for conditions such as Crohn's disease and ulcerative colitis.
Etymology
The name "Anrukinzumab" is derived from the International Nonproprietary Names (INN), where "anru" refers to anti-human, "kin" refers to interleukin, "zu" refers to humanized, and "mab" refers to monoclonal antibody.
Mechanism of Action
Anrukinzumab works by targeting and neutralizing interleukin 13 (IL-13), a cytokine that plays a crucial role in the pathogenesis of various inflammatory and autoimmune diseases. By blocking the action of IL-13, Anrukinzumab can help reduce inflammation and alleviate symptoms associated with these conditions.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Interleukin 13: A type of protein in the body that can promote inflammation, fibrosis, and immune responses.
- Autoimmune Disease: A condition in which your immune system mistakenly attacks your body.
- Crohn's Disease: A type of inflammatory bowel disease (IBD) that causes inflammation of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.
- Ulcerative Colitis: A chronic, inflammatory bowel disease that causes inflammation in the digestive tract.
External links
- Medical encyclopedia article on Anrukinzumab
- Wikipedia's article - Anrukinzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski